

## Global Biotechnology Seminar and Discussion

### **Genomics in Everyday Care: Commercializing Technologies for Low Cost, Routine Genomic Testing**



**Bob Terbrueggen, PhD**

President and CEO

DxTerity Diagnostics

**Thursday, February 9, 2017**

3 - 4 p.m. seminar

4 - 5 p.m. discussion

East Conference Room

Norris Medical Library, Health Science Campus

Bob Terbrueggen is the Founder and CEO of DxTerity Diagnostics [www.DxTerity.com](http://www.DxTerity.com), a Los Angeles based patient-centric diagnostics company specializing in the development of cost-effective high precision genomic tests. Key to DxTerity's development process is its Direct-to-Patient (D2P) genomic study platform which powers population scale clinical studies using self-collected fingerstick blood from the convenience of home resulting in real-world patient data.

Bob received his Ph.D. in Chemistry from the California Institute of Technology, and his BS in Chemistry and Molecular Biology for the University of Michigan. Bob started his career at Clinical Micro Sensors (CMS) in Pasadena, CA. At CMS, he was the Director of R&D where he oversaw the development of the world's first bio-electronic DNA detection platform, the e-Sensor. Motorola acquired CMS in 2000 for \$300 million, and the e-Sensor is currently being used to deliver several FDA approved diagnostic tests. In 2005, Bob co-founded NanoBiomics in Tempe, AZ. NanoBiomics was developing genomic tests for the diagnosis and prognosis of cancer, and it was named the 2005 best start-up of the year by the Arizona Biotech Association. In late 2005, NanoBiomics was acquired by the Molecular Profiling Institute. Bob then went on to start DxTerity Diagnostics. Bob is an inventor on 19 approved U.S. patents and more than 20 pending applications.